Triplet Therapy May Not Provide Additional Benefit in Older Patients With CLL
Patients 65 years and older treated with Venclexta, Imbruvica and Gazyva for CLL had similar rates of progression-free survival compared with those treated with Imbruvica and Gazyva.
United States Jennifer Woyach James Leukemia Research Program Ohio State University Comprehensive Cancer Center American Society Of Clinical Oncology Annual Meeting Adding Venclexta
Source: curetoday.com